People diagnosed with headache had a greater risk for attempting and completing suicide, according to results of a cohort ...

Headaches and migraine, including mild tension headaches, are linked to an increased risk of suicide, according to new ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

Tufts Medical Center Dr. Alice Connors-Kellgren on why a new study is finding a link between headaches and a spike in suicide attempts.

"Patients diagnosed with headache may benefit from concurrent behavioral health evaluation and treatment," researchers said.

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Exploring Analgesics as a Key Painkiller Types & Their Role in Pain ReliefUnited States, New York, Feb. 04, 2025 (GLOBE ...

People suffering from headaches, even if they are relatively mild, may be more prone to committing suicide, a study warns.

HEADACHES increase the odds of suicide, a new study says. While migraines and cluster headaches have already been linked to higher suicide risk, people with milder types, such as tension ...

The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...

The study found that soreness, headaches, and fatigue were the most common side effects of the treatment but that the did not last longer than 2 hours. There were no serious side effects reported.